Date: 2015-04-30
Type of information: Private placement
Company: Pfenex (USA - CA)
Investors:
Amount: $38 million
Funding type: private placement
Planned used:
Others: * On April 30, 2015, Pfenex, a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, announced the closing of its previously announced underwritten public offering of 6,750,000 shares of its common stock at a public offering price of $15.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock from certain selling stockholders. Pfenex sold 2,610,000 shares of common stock and certain existing stockholders of Pfenex sold 4,140,000 shares of common stock. The net proceeds to Pfenex from this offering were approximately $38 million, after deducting underwriting discounts and commissions but before deducting estimated offering expenses payable by Pfenex. * On April 24, 2015, Pfenex announced the pricing of its follow-on public offering of 6,000,000 shares of its common stock at a price to the public of $15.50 per share. Of the shares being offered, 2,610,000 are being offered by Pfenex and the remaining 3,390,000 shares are being offered by existing stockholders. Pfenex will not receive any proceeds from the shares sold by existing stockholders. In addition, the underwriters have a 30-day option to purchase up to 750,000 additional shares of common stock from certain existing stockholders. A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission.
Therapeutic area:
